Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response
Authors:
- Alice C. RodriguesAlice C. Rodrigues
- Paula M. S. PerinPPPaula M. S. Perin
- Sheila G. PurimSPSheila G. Purim
- Vivian N. SilbigerVSVivian N. Silbiger
- Fabiana D. V. GenvigirFGFabiana D. V. Genvigir
- Maria Alice V. WillrichMWMaria Alice V. Willrich
- Simone S. AraziSASimone S. Arazi
- Andre D. LuchessiALAndre D. Luchessi
- Mario H. HirataMHMario H. Hirata
- Marcia M. S. BernikMBMarcia M. S. Bernik
- Egidio L. DoreaEDEgidio L. Dorea
- Carla SantosCSCarla Santos
Open Access
- 9 September 2011
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 12 (9) , 5815-5827
Abstract
Aims: The relationship between variants in SLCO1B1 and SLCO2B1 genes and lipid-lowering response to atorvastatin was investigated. Material and Methods: One-hundred-thirty-six unrelated individuals with hypercholesterolemia were selected and treated with atorvastatin (10 mg/day/4 weeks). They were genotyped with a panel of ancestry informative markers for individual African component of ancestry (ACA) estimation by SNaPshot® and SLCO1B1 (c.388A>G, c.463C>A and c.521T>C) and SLCO2B1 (−71T>C) gene polymorphisms were identified by TaqMan® Real-time PCR. Results: Subjects carrying SLCO1B1 c.388GG genotype exhibited significantly high low-density lipoprotein (LDL) cholesterol reduction relative to c.388AA+c.388AG carriers (41 vs. 37%, p = 0.034). Haplotype analysis revealed that homozygous of SLCO1B1*15 (c.521C and c.388G) variant had similar response to statin relative to heterozygous and non-carriers. A multivariate logistic regression analysis confirmed that c.388GG genotype was associated with higher LDL cholesterol reduction in the study population (OR: 3.2, CI95%:1.3–8.0, p < 0.05). Conclusion: SLCO1B1 c.388A>G polymorphism causes significant increase in atorvastatin response and may be an important marker for predicting efficacy of lipid-lowering therapy.Keywords
This publication has 40 references indexed in Scilit:
- Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of StatinsCirculation Research, 2010
- OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteersJournal of Clinical Pharmacy and Therapeutics, 2010
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide StudyNew England Journal of Medicine, 2008
- Organic anion transporting polypeptide-1B1 haplotypes in Chinese patientsActa Pharmacologica Sinica, 2007
- SLCO1B1 521T→C functional genetic polymorphism and lipid‐lowering efficacy of multiple‐dose pravastatin in Chinese coronary heart disease patientsBritish Journal of Clinical Pharmacology, 2007
- Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapyJournal of Human Genetics, 2006
- Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of theSLCO1B1andABCB1genesBritish Journal of Clinical Pharmacology, 2006
- An association study of 43 SNPs in 16 candidate genes with atorvastatin responseThe Pharmacogenomics Journal, 2005
- High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)Pharmacogenetics, 2004
- Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 1995